On August 9, 2023, ImmunoPrecise Antibodies Ltd announced that it has issued a statement in response to the filing made on July 7, 2023, by Ingalls & Snyder LLC, stating that the Company?s Board of Directors and management team value constructive input and welcome open communication with shareholders including Ingalls & Snyder, committed to acting in the best interest of the Company and strive to have the optimal board of directors? composition to attain Company?s strategic priorities and to maximize long-term shareholder value, and had opened the dialogue with Ingalls & Snyder LLC and will continue to engage in discussions with them as we carefully consider their views.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.01 USD | +2.02% | 0.00% | -40.94% |
06-27 | ImmunoPrecise Antibodies Ltd. Appoints Kristin Taylor as Permanent Chief Financial Officer | CI |
06-25 | ImmunoPrecise Antibodies Unit, PGxAI to Develop AI Model to Predict Treatment Responses | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.94% | 26.58M | |
+2.99% | 95.18B | |
-4.34% | 37.55B | |
-10.41% | 33.75B | |
+75.79% | 28.2B | |
-14.61% | 15.63B | |
-3.46% | 13.63B | |
-12.31% | 11.5B | |
+184.77% | 10.81B | |
-54.13% | 9.23B |
- Stock Market
- Equities
- IPA Stock
- News ImmunoPrecise Antibodies Ltd.
- ImmunoPrecise Antibodies Ltd Issues a Response to Ingalls & Snyder LLC Filing